ReviewEClinicalMedicine2026

Twelve mutations, three trials, and five different labels: PARP inhibitors regulatory inconsistencies in prostate cancers.

Sahar Barjesteh van Waalwijk van Doorn-Khosrovani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.